HUTCHMED (China) Limited

Equities

HCM

KYG4672N1198

Pharmaceuticals

Delayed London S.E. 05:25:07 2024-07-09 am EDT 5-day change 1st Jan Change
267 GBX +0.77% Intraday chart for HUTCHMED (China) Limited -2.18% -5.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Advance Late Afternoon MT
Hutchmed's tazemetostat given priority review in China AN
Sector Update: Health Care Stocks Advance in Afternoon Trading MT
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China MT
Hong Kong Stocks Rally on US Rate Cut Hopes, EU's Indecisive on Tariffs on Chinese EVs MT
Hutchmed's NDA for Lymphoma Drug Gets Priority Review Status in China MT
HUTCHMED Limited Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review CI
Takeda's Cancer Drug Gets European Commission Approval MT
Hutchmed China notes Takeda obtains EU approval for Fruzaqla AN
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment MT
Takeda Receives European Commission Approval for Colorectal Cancer Treatment MT
Hutchmed celebrates "promising" results for sovleplenib in China AN
Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology CI
Transcript : HUTCHMED Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Hutchmed (China) begins trial of menin inhibitor HMPL-506 AN
Hutchmed Begins Phase 1 Trial of Potential Treatment for Acute Myeloid Leukemia MT
Hutchmed (China)'a Cancer Drug Phase I Clinical Trial Begins MT
HUTCHMED Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China CI
HUTCHMED Limited Announces Results from FRUTIGA, HUTCHMED's Phase III Trial of Fruquintinib in Combination with Paclitaxel for the Treatment of Second-Line Advanced Gastric Cancer CI
HUTCHMED Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine CI
HUTCHMED Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology CI
Hutchmed (China) Chairman Resigns, Successor Named MT
Hutchmed China Simon To leaves role, succeeded by Dan Eldar AN
Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor MT
HUTCHMED Limited Announces Executive Changes CI
Chart HUTCHMED (China) Limited
More charts
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.4 USD
Average target price
5.971 USD
Spread / Average Target
+75.63%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. HCM Stock
  4. News HUTCHMED (China) Limited
  5. Hutchmed Announces Retirement of Simon To as Chairman, Names Dan Eldar Successor